

(19) **DANMARK**

(10) **DK/EP 1649017 T4**



Patent- og
Varemærkestyrelsen

(12) **Oversættelse af ændret
europæisk patentskrift**

-
- (51) Int.Cl.: **C 12 N 15/11 (2006.01)** **A 61 K 38/00 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2014-12-01**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om opretholdelse af patentet i ændret form: **2014-08-27**
- (86) Europæisk ansøgning nr.: **04743564.9**
- (86) Europæisk indleveringsdag: **2004-07-23**
- (87) Den europæiske ansøgnings publiceringsdag: **2006-04-26**
- (86) International ansøgning nr.: **GB2004003235**
- (87) Internationalt publikationsnr.: **WO2005012524**
- (30) Prioritet: **2003-07-25 GB 0317466**
- (84) Designerede stater: **AT BE BG CH CY CZ DE DK EE ES FI FR GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR**
- (73) Patenthaver: **THE UNIVERSITY OF SHEFFIELD, Western Bank, Sheffield, South Yorkshire S10 2TN, Storbritannien**
- (72) Opfinder: **HELLEDAY, Thomas, Erik Dahlbergsgatan 38, S-115 32 Stockholm, Sverige**
- (74) Fuldmægtig i Danmark: **Awapatent A/S, Rigensgade 11, 1316 København K, Danmark**
- (54) Benævnelse: **Anvendelse af RNA i inhiberende PARP aktivitet til fremstillingen af et lægemiddel til behandlingen af cancer**
- (56) Fremdragne publikationer:
WO-A-02/12239
WO-A-95/24379
MASSUDA EDMOND ET AL: "GPI 6150, a PARP inhibitor, down-regulates metastasis associated S100A4 (Mts1) and suppresses invasion of breast cancer cells in vitro." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 44, July 2003 (2003-07), pages 867-868, XP001181719 & 94TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; WASHINGTON, DC, USA; JULY 11-14, 2003 ISSN: 0197-016X
WELTIN D ET AL: "EFFECT OF 6(5H)-PHENANTHRIDINONE, AN INHIBITOR OF POLY(ADP-RIBOS) POLYMERASE, ON CULTURED TUMOR CELLS" ONCOLOGY RESEARCH, PERGAMON PRESS, NEW YORK, NY, US, vol. 6, no. 9, 1994, pages 399-403, XP008003298 ISSN: 0965-0407
SCHULTZ NIKLAS ET AL: "Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination." NUCLEIC ACIDS RESEARCH, vol. 31, no. 17, 1 September 2003 (2003-09-01), pages 4959-4964, XP002305998 ISSN: 0305-1048
LARMINAT FLORENCE ET AL: "Deficiency in BRCA2 leads to increase in non-conservative homologous recombination" ONCOGENE, vol. 21, no. 33, 1 August 2002 (2002-08-01), pages 5188-5192, XP002305999 ISSN: 0950-9232
SHALL SYDNEY ET AL: "Poly (ADP-ribose) polymerase-1: What have we learned from the deficient mouse

Fortsættes ...

model?" MUTATION RESEARCH, vol. 460, no. 1, 30 June 2000 (2000-06-30), pages 1-15, XP002306000 ISSN: 0027-5107

DATABASE EMBL 23 March 2001 (2001-03-23), STRAUSBERG, R.: XP002306001 retrieved from EBI Database accession no. BG483078

ELBASHIR SAYDA M ET AL: "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 411, no. 6836, 24 May 2001 (2001-05-24), pages 494-498, XP002206451 ISSN: 0028-0836

EP 1 649 017 B2

Description

[0001] This invention relates to the use of an agent that inhibits the activity of an enzyme which mediates the repair of DNA strand breaks in the treatment of certain forms of cancer in particular breast cancer.

5 [0002] Homologous recombination (HR) has been shown to play an important role in repair of damage occurring at DNA replication forks in mammalian cells (2). Thus, cells deficient in HR show retarded growth and exhibit higher level of genetic instability. It is believed that genetic instability due to loss of HR repair in human cancers significantly contributes to the development of cancer in these cells (1).

10 [0003] Post transcriptional modification of nuclear proteins by poly(ADP-ribosyl)ation (PARP) in response to DNA strand breaks plays an important role in DNA repair, regulation of apoptosis, and maintenance of genomic stability.

[0004] Poly(ADP-ribose) Polymerase (PARP-1) is an abundant nuclear protein in mammalian cells that catalyses the formation of poly(ADP-ribose) (PAR) polymers using NAD⁺ as substrate. Upon DNA damage, PARP-1 binds rapidly to a DNA strand break (single strand or double strand) and catalyses the addition of negatively charged PAR chains to itself (automodification) and other proteins (see [3, 4] for reviews). The binding of PARP-1 to DNA strand breaks is 15 believed to protect DNA lesions from further processing until PARP-1 is dissociated from the break by the accumulated negative charge resulting from PAR polymers (5,6).

[0005] Although PARP-1 has been implicated in several nuclear processes, such as modulation of chromatin structure, DNA replication, DNA repair and transcription, PARP-1 knockout mice develop normally (7). Cells isolated from these mice exhibit a hyper recombination phenotype and genetic instability in the form of increased levels of SCE, micronuclei 20 and tetraploidy (8-10). Genetic instability may also occur in these PARP-1 knockout mice through telomere shortening, increased frequency of chromosome fusion and aneuploidy (11), although all of these results could not be repeated in another set of PARP-1 knock-out mice (12). In the former mice knockout, PARP-1 null mutation rescue impaired V(D)J recombination in SCID mice (13). These results support the view suggested by Lindahl and coworkers that PARP-1 has a protective role against recombination (5). They proposed that binding of PARP-1 to DNA strand breaks prevents the 25 recombination machinery from recognizing and processing DNA lesions or, alternatively, that the negative charges accumulated following poly ADP-ribosylation repel adjacent recombinogenic DNA sequences. Only the latter model is consistent with inhibition of PARP-1 itself and expression of a dominant negative mutant PARP-1, inducing SCE, gene amplification and homologous recombination (HR [14-18]).

[0006] Studies based on treating cells with PARP inhibitors or cells derived from PARP-1 or PARP-2 knockout mice 30 indicate that the suppression of PARP-1 activity increases cell susceptibility to DNA damaging agents and inhibits strand break rejoining (3, 4, 8-11, 19, 20, 47).

[0007] Inhibitors of PARP-1 activity have been used in combination with traditional anticancer agents such as radio 35 therapy and chemotherapy (21). The inhibitors were used in combination with methylating agents, topoisomerase poisons and ionising radiations and were found to enhance the effectiveness of these forms of treatment. Such treatments, however, are known to cause damage and death to non cancerous or "healthy" cells and are associated with unpleasant side effects.

[0008] There is therefore a need for a treatment for cancer that is both effective and selective in the killing of cancer cells and which does not need to be administered in combination with radio or chemotherapy treatments.

40 [0009] The present inventors have surprisingly found that cells deficient in homologous recombination (HR) are hypersensitive to PARP inhibitors as compared to wild type cells. This is surprising since PARP-1 knockout mice live normally thereby indicating that PARP-1 is not essential for life. Thus, it could not be expected that cells would be sensitive to PARP inhibition.

[0010] According to a first aspect of the invention there is provided the use of a PARP-1 inhibitor in the manufacture of a medicament for the treatment of cancer cells defective in homologous recombination in a human as set out in claim 1.

45 [0011] Preferably the medicament is a pharmaceutical composition consisting of the PARP inhibitor in combination with a pharmaceutically acceptable carrier or diluent.

[0012] The specific sensitivity of HR defective tumours to PARP-1 inhibition means that normally dividing cells in the patient will be unaffected by the treatment. Treatment of HR defective cancer cells using a PARP inhibitor also has the advantage that it does not need to be administered as a combination therapy along with conventional radio or chemo- 50 therapy treatments thereby avoiding the side effects associated with these conventional forms of treatment.

[0013] A genetic defect in a gene which mediates homologous recombination may be due to a mutation in, the absence of, or defective expression of, a gene encoding a protein involved in HR.

[0014] A PARP inhibitor may be used in the manufacture of a medicament for inducing apoptosis in HR defective cells.

55 [0015] A method of inducing apoptosis in HR defective cells in a mammal may comprise administering to the mammal a therapeutically effective amount of a PARP inhibitor.

[0016] By causing apoptosis in HR defective cells it should be possible to reduce or halt the growth of a tumour in the mammal.

[0017] Preferably, the HR defective cells are cancer cells.

EP 1 649 017 B2

[0018] Cancer cells defective in HR may partially or totally deficient in HR. Preferably the cancer cells are totally deficient in HR.

[0019] The term "cancer" or "tumour" includes lung, colon, pancreatic, gastric, ovarian, cervical, breast or prostate cancer. The cancer may also include skin, renal, liver, bladder or cerebral cancer. The cancer is in a human.

5 **[0020]** The cancer to be treated may be an inherited form of cancer wherein the patient to be treated has a familial predisposition to the cancer. Preferably, the cancer to be treated is gene-linked hereditary cancer. In a preferred embodiment of the invention the cancer is gene-linked hereditary breast cancer.

10 **[0021]** In a preferred aspect, the PARP inhibitor is useful in the treatment of cancer cells defective in the expression of a gene involved in HR. Genes with suggested function in HR include XRCC1, ADPRT (PARP-1), ADPRTL2 (PARP-2), CTPS, RPA, RPA1, RPA2, RPA3, XPD, ERCC1, XPF, MMS19, RAD51, RAD51B, RAD51C, RAD51D, DMC1, XRCC2, XRCC3, BRCA1, BRCA2, RAD52, RAD54, RAD50, MRE11, NBS1, WRN, BLM, Ku70, Ku80, ATM, ATR, chk1, chk2, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, RAD1, RAD9, FEN-1, Mus81, Eme1, DDS1, BARD (see (2, 3, 5, 22-28) for reviews).

15 **[0022]** A gene involved in HR may be a tumour suppressor gene. The invention thus provides for the treatment of cancer cells defective in the expression of a tumour suppressor gene. Preferably, the tumour suppressor gene is BRCA1 or BRCA2.

20 **[0023]** Breast cancer is the most common cancer disease among women in the Western world today. Certain families have strong predisposition for breast cancer, which is often owing to an inherited mutation in one allele of either BRCA1 or BRCA2. However, these patients still maintain one functional allele. Thus, these patients develop normally and have no phenotypic consequence from this mutation. However, in one cell, the functional allele might be lost, making this cell cancerous and at the same time deficient in homologous recombination (HR). This step is critical for the onset of a tumour (1).

[0024] The present inventors have surprisingly found that BRCA2 deficient cells are 100 times more sensitive to the cytotoxicity of the PARP inhibitor, NU1025, than wild type cells.

25 **[0025]** Thus A PARP inhibitor may be used in the manufacture of a medicament for the treatment of cancer cells defective in HR, e.g due to the loss of BRCA1 and/or BRCA2 expression.

[0026] The cancer cells to be treated may be partially or totally deficient in BRCA1 or BRCA2 expression. BRCA1 and BRCA2 mutations can be identified using multiplex PCR techniques, array techniques (29, 30) or using other screens known to the skilled person.

30 **[0027]** PARP inhibitors useful in the present invention may be inhibitors of PARP-1, (see 31 for a review).

35 **[0028]** PARP inhibitors useful in the present invention include benzimidazole-carboxamides, quinazolin-4-[3H]-ones and isoquinoline derivatives (e.g.2-(4-hydroxyphenyl)benzimidazole-4-carboxamide (NU1085), 8-hydroxy-2-methyl-quinazolin-4-[3H]one (NU1025); 6(5H)phenanthridinone; 3 aminobenzamide; benzimidazole-4-carboxamides (BZ1-6) and tricyclic lactam indoles (T11-5) [32]. Further inhibitors of PARP may be identified either by design [33] or the novel FlashPlate assay [34].

[0029] The PARP inhibitor formulated as a pharmaceutical composition may be administered in any effective, convenient manner effective for targeting cancer cells including, for instance, administration by oral, intravenous, intramuscular, intradermal, intranasal, topical routes among others. Carriers or diluents useful in the pharmaceutical composition may include, but are not limited to saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof.

40 **[0030]** In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion. The inhibitor may be administered directly to a tumour or may be targeted to the tumour via systemic administration.

45 **[0031]** A therapeutically effective amount of the inhibitor is typically one which is sufficient to achieve the desired effect and may vary according to the nature and severity of the disease condition, and the potency of the inhibitor. It will be appreciated that different concentrations may be employed for prophylaxis than for treatment of an active disease.

[0032] For administration to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be up to 100mg/kg, for example from 0.01mg/kg to 50 mg/kg body weight, typically up to 0.1, 0.5, 1.0, 2.0 5.0, 10, 15, 20 or 30mg/kg body weight. Ultimately, however, the amount of inhibitor administered and the frequency of administration will be at the discretion of a physician.

50 **[0033]** A therapeutic advantage of using PARP inhibitors to treat cancer cells is that only very low doses are needed to have a therapeutic effect in treating cancer thereby reducing systemic build up of the inhibitors and any associated toxic effects.

[0034] A preferred aspect of the invention provides an agent which is an inhibitory RNA (RNAi) molecule.

55 **[0035]** A technique to specifically ablate gene function is through the introduction of double stranded RNA, also referred to as inhibitory RNA (RNAi), into a cell which results in the destruction of mRNA complementary to the sequence included in the RNAi molecule. The RNAi molecule comprises two complementary strands of RNA (a sense strand and an antisense strand) annealed to each other to form a double stranded RNA molecule. The RNAi molecule is typically derived from exonic or coding sequence of the gene which is to be ablated.

EP 1 649 017 B2

[0036] Preferably said RNAi molecule is derived from the nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of:

- a) a nucleic acid sequence as represented by the sequence in Figure 9, or fragment thereof;
- b) a nucleic acid sequence which hybridises to the nucleic acid sequences of Figure 9, and encodes a gene for PARP;
- c) a nucleic acid sequence which comprise sequences which are degenerate as a result of the genetic code to the nucleic acid sequences defined in (a) and (b).

[0037] Recent studies suggest that RNAi molecules ranging from 100-1000bp derived from coding sequence are effective inhibitors of gene expression. Surprisingly, only a few molecules of RNAi are required to block gene expression which implies the mechanism is catalytic. The site of action appears to be nuclear as little if any RNAi is detectable in the cytoplasm of cells indicating that RNAi exerts its effect during mRNA synthesis or processing.

[0038] More preferably said RNAi molecule according has a length of between 10 nucleotide bases (nb) -1000nb. Even more preferably said RNAi molecule has a length of 10nb; 20nb; 30nb; 40nb; 50nb; 60nb; 70nb; 80nb; 90nb; or 100bp. Even more preferably still said RNAi molecule is 21nub in length.

[0039] Even more preferably still the RNAi molecule comprises the nucleic acid sequence aaa agc cau ggu gga gua uga (PARP-1)

[0040] The RNAi molecule may comprise modified nucleotide bases.

[0041] Preferred features of each aspect of the invention are as for each of the other aspects *mutatis mutandis*.

[0042] The present invention will now be described by way of example only with reference to the accompanying figures, wherein:

Figure 1 is a graph demonstrating that HR deficient cells are hypersensitive to the toxic effect caused by inhibition of PARP-1. Colony outgrowth of the Chinese hamster cell lines AA8 (wild-type), irs1SF (deficient in HR[4]), CXR3 (irs1SF complemented with XRCC3 [2]), V79 (wild-type), irs1 (deficient in HR[5]) or irs1X2.2 (irs1 complemented with XRCC2 [1]) upon exposure to 3-AB (A), ISQ (B) or NU1025 (C). The means (symbols) and standard deviation (bars) of at least three experiments are shown. Colony outgrowth assay was used;

Figure 2 is a graph showing cell survival in the presence of PARP inhibitor NU1025 in wt V79 cells, BRCA2 deficient VC-8 cells and VC-8 cells complemented with functional BRCA2 gene (VC-8#13, VC-8+B2). Colony outgrowth assay was used;

Figure 3 is a histogram showing the percentage of the cells in apoptosis following a 72 hour incubation with NU1025;

Figure 4. (a) Western blot analysis of protein lysates isolated from MCF-7 (p53^{wt}) or MDA-MB-231 (p53^{mut}) breast cancer cells following 48 hours transfection with siRNA. (b) Colony outgrowth of siRNA-treated MCF-7 cells or (c) MDA-MB-231 cells following exposure to the PARP inhibitor NU1025. The means (symbols) and standard deviation (bars) of at least three experiments are shown.

Figure 5. BRCA2 deficient cells fail to repair a recombination lesion formed at replication forks by inhibitors of PARP. (a) Visualization of double strand breaks (DSBs) in BRCA2 proficient or deficient cells following a 24-hour treatment with NU1025 (0.1 mM) by pulse-field gel electrophoresis. Hydroxyurea 2 mM was used as a positive control. (b) Visualisation of γ H2Ax foci in untreated V-C8+B2 and V-C8 cells. Number of cells containing γ H2Ax foci (c) or RAD51 foci (d) visualised in V-C8+B2 and V-C8 cells following a 24-hour treatment with NU1025 (10 μ M). The means (symbols) and standard errors (bars) of three to nine experiments are shown. (e) A suggested model for cell death induced in BRCA2 deficient cells.

Figure 6. PARP-1 and not PARP-2 is important in preventing formation of a recombinogenic lesion, causing death in absence of BRCA2. (a) RT-PCR on RNA isolated from SW480SN.3 cells treated with BRCA2, PARP-1 and PARP-2 siRNA in combinations as shown for 48 hours. (b) Clonogenic survival following 48-hours depletion of BRCA2, PARP-1 and PARP-2. The means (symbols) and standard deviation (bars) of at least three experiments are shown. Two and three stars designate statistical significance in *t-test* $p < 0.01$ and $p < 0.001$, respectively. (c) Western blot for PARP-1 in SW480SN.3 cells treated with different siRNA.

Figure 7. (a) Visualisation of PAR polymers in untreated and (b) thymidine treated V79 cells (5 mM for 24 hours). (c) Percentage cells containing >10 sites of PARP activity following treatment with hydroxyurea (0.2 mM) and thymidine (5 mM). At least 300 nuclei were counted for each treatment and experiment. (d) Survival of V-C8+B2 cells following co-treatment with hydroxyurea or (e) thymidine and NU1025 (10 μ M). (f) The activity of PARP was

EP 1 649 017 B2

measured by the level of free NAD(P)H ¹¹, following treatment with MMS, hydroxyurea (0.5 mM) or thymidine (10 mM). The means (symbol) and standard deviation (error bars) from at least three experiments are depicted.

Figure 8. (a) Visualisation of PAR polymers in untreated V-C8 and (b) V-C8+B2 cells. (c) Quantification of percentage cells containing >10 sites of PARP activity in untreated V-C8 and V-C8+B2 cells. (d) Level of NAD(P)H measured in untreated V-C8 and V-C8+B2 cells. Three stars designate p<0.001 in t-test. (e) Visualization of RAD51 and sites of PARP activity in V79 cells following a 24-hour thymidine treatment (5 mM). (f) A model for the role of PARP and HR at stalled replication forks.

Figure 9 is the human cDNA sequence of PARP-1;

Figure 10 is the human cDNA sequence of PARP-2;

Figure 11 is the human cDNA sequence of PARP-3;

Figure 12 is the human gDNA sequence of Tankyrase 1;

Figure 13 is the human mRNA sequence of Tankyrase 2;

Figure 14 is the human mRNA sequence of VPARP.

Materials and Methods

Cytotoxicity of PARP inhibitors to HR-defective cells: XRCC2, XRCC3 or BRCA2

Cell culture

[0043] The irs1, irs1X2.1 and V79-4 cell lines were a donation from John Thacker [40] and the AA8, irs1SF and CXR3 cell lines were provided by Larry Thompson [41].

[0044] The VC-8, VC-8+B2, VC-8#13 were a gift from Malgorzata Zdzienicka [42]. All cell lines in this study were grown in Dulbecco's modified Eagle's Medium (DMEM) with 10% Foetal bovine serum and penicillin (100 U/ml) and streptomycin sulphate (100 µg/mL) at 37°C under an atmosphere containing 5% CO₂.

Toxicity assay - colony outgrowth assay

[0045] 500 cells suspended in medium were plated onto a Petri dish 4 hours prior to the addition of 3-AB, ISQ or NU1025. ISQ and NU1025 were dissolved in DMSO to a final concentration of 0.2% in treatment medium. 7 - 12 days later, when colonies could be observed, these colonies were fixed and stained with methylene blue in methanol (4 g/l). Colonies consisting of more than 50 cells were subsequently counted.

Apoptosis experiments

[0046] 0.25x 10⁶ cells were plated onto Petri dishes and grown for 4 hours before treatment with NU1025. After 72 hours, cells were trypsinized and resuspended with medium containing any floating cells from that sample. The cells were pelleted by centrifugation and resuspended for apoptosis analysis with FITC-conjugated annexin-V and propidium iodide (PI) (ApoTarget, Biosource International) according to manufacturer's protocol. Samples were analysed by flow cytometry (Becton-Dickenson FACSsort, 488 nm laser), and percentage of apoptotic cells was determined by the fraction of live cells (PI-negative) bound with FITC-conjugated annexin-V.

Immunofluorescence

[0047] Cells were plated onto coverslips 4 h prior to 24-h treatments as indicated. Following treatments the medium was removed and coverslips rinsed once in PBS at 37°C and fixed as described elsewhere [2]. The primary antibodies and dilutions used in this study were; rabbit polyclonal anti PAR (Trevigen; 1:500), goat polyclonal anti Rad51 (C-20, Santa Cruz; 1:200) and rabbit polyclonal anti Rad51 (H-92, Santa Cruz; 1:1000). The secondary antibodies were Cy-3-conjugated goat anti-rabbit IgG antibody (Zymed; 1:500), Alexa 555 goat anti-rabbit F(ab')₂ IgG antibody (Molecular Probes; 1:500), Alexa 546 donkey anti-goat IgG antibody (Molecular Probes; 1:500) and Alexa 488 donkey anti-rabbit IgG antibody (Molecular Probes; 1:500). Antibodies were diluted in PBS containing 3% bovine serum albumin. DNA was

EP 1 649 017 B2

stained with 1 µg/ml To Pro (Molecular Probes). Images were obtained with a Zeiss LSM 510 inverted confocal microscope using planapochromat 63X/NA 1.4 oil immersion objective and excitation wavelengths 488, 546 and 630 nm. Through focus maximum projection images were acquired from optical sections 0.50 µm apart and with a section thickness of 1.0 µm. Images were processed using Adobe PhotoShop (Abacus Inc). At least 300 nuclei were counted on each slide and those containing more than 10 RAD51 foci or sites of PARP activity were classified as positive.

PARP activity assays

[0048] A water-soluble tetrazolium salt (5mM WST-8) was used to monitor the amount of NAD(P)H through its reduction to a yellow coloured formazan dye[43]. 5000 cells were plated in at least triplicate into wells of a 96 well plate and cultured in 100µl normal growth media for 4 h at 37°C. CK8 buffer (Dojindo Molecular Technology, Gaithersburg, USA), containing WST-8, was then added either with or without treatment with DNA damaging agents at concentrations indicated. Reduction of WST-8 in the presence of NAD(P)H was determined by measuring visible absorbance (OD₄₅₀) every 30 min. A medium blank was also prepared containing just media and CK8 buffer. Changes in NAD(P)H levels were calculated by comparing the absorbance of wells containing cells treated with DNA damaging agents and those treated with DMSO alone. Alternately relative levels of NAD(P)H in different cells lines were calculated after 4 h incubation in CK8 buffer.

[0049] The ability of NU1025 to inhibit PARP-1 activity was also assayed in permeabilised cells using a modification of the method of Halldorsson *et al* [44], and described in detail elsewhere [45]. Briefly: 300 µl of NU1025-treated (15 min) permeabilised cells were incubated at 26°C with oligonucleotide (final conc. 2.5 µg/ml), 75 µM NAD + [³²P] NAD (Amersham Pharmacia, Amersham, UK) in a total volume of 400 µl. The reaction was terminated after 5 min by adding ice cold 10%TCA 10%Na Ppi for 60 min prior to filtering through a Whatman GF/C filter (LabSales, Maidstone, UK), rinsed 6x with 1% TCA 1% NaPpi, left to dry and incorporated radioactivity was measured to determine PARP-1 activity. Data are expressed as pmol NAD incorporated/10⁶ cells by reference to [³²P] NAD standards.

Pulse-field gel electrophoresis

[0050] 1.5x10⁶ cells were plated onto 100 mm dishes and allowed 4 h for attachment. Exposure to drug was for 18 h after which cells were trypsinised and 10⁶ cells melted into each 1% agarose insert. These inserts were incubated as described elsewhere (8) and separated by pulse-field gel electrophoresis for 24 h (BioRad; 120° angle, 60 to 240 s switch time, 4 V/cm). The gel was subsequently stained with ethidium bromide for analysis.

siRNA treatment

[0051] Predesigned BRCA2 SMARTpool and scrambled siRNAs were purchased (Dharmacon, Lafayette, CO). 10000 cells seeded onto 6 well plates and left over night before transfected with 100nM siRNA using Oligofectamine Reagent (Invitrogen) according to manufacturers instructions. Cells were then cultured in normal growth media for 48 h prior to trypsinisation and replating for toxicity assays. Suppression of BRCA2 was confirmed by Western blotting (as described previously [46]) of protein extracts treated with siRNA with an antibody against BRCA2 (Oncogene, Nottingham, UK).

EXAMPLESHomologous recombination deficient cells are hypersensitive to PARP-1 inhibition

[0052] To investigate the involvement of HR in cellular responses to inhibition of PARP-1, the effects of PARP-1 inhibitors on the survival of HR repair deficient cell lines were studied. It was found that cells deficient in HR (i.e., irs1SF which is defective in XRCC3 or irs1 which is defective in XRCC2 [see Table 1] were very sensitive to the toxic effect of 3-aminobenzamide (3-AB) and to two more potent inhibitors of PARP-1: 1,5-dihydroxyisoquinoline (ISQ; [37]) or 8-hydroxy-2-methylquinazolinone (NU1025 [38, 39]) (Figure 1). The sensitivity in irs1SF cells to 3-AB, ISQ or NU1025 was corrected by the introduction of a cosmid containing a functional XRCC3 gene (CXR3). Similarly, the sensitivity in irs1 cells to 3-AB, ISQ or NU1025 was corrected by the introduction of a cosmid containing a functional XRCC2 gene (irs1X2.2).

BRCA2 deficient cells are hypersensitive to PARP-1 inhibition

[0053] The survival of BRCA2 deficient cells (VC8) and wild type cells (V79Z) in the presence of inhibitors of PARP-1 was investigated. It was found that VC8 cells are very sensitive to the toxic effect of NU1025 (Figure 2). The sensitivity in VC8 cells was corrected by the introduction of a functional BRCA2 gene either on chromosome 13 (VC8#13) or on an overexpression vector (VC8+B2). This result demonstrates that the sensitivity to PARP-1 inhibitors is a direct con-

EP 1 649 017 B2

sequence of loss of the BRCA2 function.

[0054] To investigate if inhibition of PARP-1 triggers apoptosis in BRCA2 deficient cells, the level of apoptosis 72 hours following exposure to NU1025 was investigated. It was found that NU1025 triggered apoptosis only in VC8 cells, showing that loss of PARP-1 activity in BRCA2 deficient cells triggers this means of death (Figure 3).

BRCA2 deficient breast cancer cells are hypersensitive to PARP-1 inhibition

[0055] It was examined whether the MCF7 (wild-type p53) and MDA-MB-231 (mutated p53) breast cancer cell lines displayed a similar sensitivity to NU1025 upon depletion of BRCA2. It was found that PARP inhibitors profoundly reduced the survival of MCF7 and MDA-MB-231 cells only when BRCA2 was depleted with a mixture of BRCA2 siRNA (Figure 4). This shows that BRCA2 depleted breast cancer cells are sensitive to PARP inhibitors regardless of p53 status.

BRCA2 deficient cells die from PARP-1 inhibition in absence of DNA double-strand breaks (DSBs) but in presence of γ H2Ax

[0056] HR is known to be involved in the repair of DSBs and other lesions that occur during DNA replication [2]. To determine whether the sensitivity of BRCA2 deficient cells is the result of an inability to repair DSBs following NU1025 treatment, the accumulation of DSBs in V79 and V-C8 cells was measured following treatments with highly toxic levels of NU1025. It was found that no DSBs were detectable by pulsed field gel electrophoretic analysis of DNA obtained from the treated cells (Figure 5A), suggesting that low levels of DSBs or other recombinogenic substrates accumulated following PARP inhibition in HR deficient cells, which trigger γ H2Ax (Figure 5B). The reason why BRCA2 deficient cells die following induction of these recombinogenic lesions is likely to be due to an inability to repair such lesions. To test this, the ability of BRCA2 deficient V-C8 cells and BRCA2 complimented cells to form RAD51 foci in response to NU1025 was determined. It was found that RAD51 foci were indeed induced in V-C8+B2 cells following treatment with NU1025 (statistically significant in *t-test* $p < 0.05$; Figure 5D). This indicates that the recombinogenic lesions trigger HR repair in these cells allowing them to survive. In contrast, the BRCA2 deficient V-C8 cells were unable to form RAD51 foci in response to NU1025 treatment (Figure 5D) indicating no HR, which would leave the recombinogenic lesions unrepaired and thus cause cell death.

PARP-1 and not PARP-2 is important in preventing formation of a recombinogenic lesion

[0057] There are two major PARPs present in the nucleus in mammalian cells, PARP-1 and PARP-2 and all reported PARP inhibitors inhibit both. In order to distinguish which PARP was responsible for the effect, we tested if the absence of PARP-1 and/or PARP-2 results in accumulation of toxic lesions, by depleting these and BRCA2 with siRNA in human cells (Figure 6a). We found that the clonogenic survival was significantly reduced when both PARP-1 and BRCA2 proteins were co-depleted from human cells (Figure 6b). Depletion of PARP-2 with BRCA2 had no effect on the clonogenic survival and depletion of PARP-2 in PARP-1 and BRCA2 depleted cells did not result in additional toxicity. These results suggest that PARP-1 and not PARP-2 is responsible for reducing toxic recombinogenic lesions in human cells. The cloning efficiency was only reduced to 60% of control in PARP-1 and BRCA2 co-depleted cells, while no HR deficient cells survived treatments with PARP inhibitors. This is likely to do with incomplete depletion of the abundant PARP-1 protein by siRNA (Figure 6c), which might be sufficient to maintain PARP-1 function in some of the cells.

PARP-1 is activated by replication inhibitors

[0058] HR is also involved in repair of lesions occurring at stalled replication forks, which may not involve detectable DSBs [2]. To test if PARP has a role at replication forks, PARP activation in cells treated cells with agents (thymidine or hydroxyurea) that retard or arrest the progression of DNA replication forks was examined. Thymidine depletes cells of dCTP and slows replication forks without causing DSBs. Hydroxyurea depletes several dNTP and block the replication fork, which is associated with the formation of DSBs at replication forks [2]. Both of these agents potently induce HR [2]. V79 hamster cells treated for 24 hours with thymidine or hydroxyurea were stained for PAR polymers. This revealed a substantial increase in the number of cells containing sites of PARP activity (Figure 7C). This result suggests a function for PARP at stalled replication forks. It was also shown that inhibition of PARP with NU1025 enhances the sensitivity to thymidine or hydroxyurea in V-C8+B2 cells (Figure 7D,E). This result suggests that PARP activity is important in repair of stalled replication forks or alternatively that it prevents the induction of death in cells with stalled replication forks.

[0059] PARP is rapidly activated at DNA single-strand breaks (SSB) and attracts DNA repair enzymes [3-6]. Methyl-methane sulphonate (MMS) causes alkylation of DNA, which is repaired by base excision repair. PARP is rapidly activated by the SSB-intermediate formed during this repair, which depletes the NAD(P)H levels (Figure 7F). We found that the activation of PARP and reduction of NAD(P)H levels is much slower following thymidine or hydroxyurea treatments. This

EP 1 649 017 B2

slow PARP activation can be explained by the indirect action of thymidine and hydroxyurea and the time required to accumulate stalled replication forks as cells enter the S phase of the cell cycle.

PARP-1 and HR have separate roles at stalled replication forks

[0060] The number sites of PARP activity in untreated BRCA2 deficient V-C8 cells was determined. It was found that more V-C8 cells contain sites of PARP activity compared to V-C8+B2 cells (Figure 8A,B,C). Also, the V-C8 cells have lower free NAD(P)H levels than the corrected cells (Figure 8D), as a likely result of the increased PARP activity. Importantly these sites of PARP activity do not overlap with RAD51 foci (Figure 8E).

[0061] The results herein suggest that PARP and HR have separate roles in the protection or rescue of stalled replication forks (Figure 8F). A loss of PARP activity can be compensated by increased HR while a loss of HR can be compensated by increased PARP activity. However, loss of both these pathways leads to accumulation of stalled replication forks and to death, as in the case of PARP inhibited BRCA2 deficient cells.

[0062] As shown in the model outlined in Figure 8F PARP and HR have complementary roles at stalled replication forks. (i) Replication forks may stall when encountering a roadblock on the DNA template. In addition, they may also stall temporarily, due to lack of dNTPs or other replication co-factors. (ii) PARP binds stalled replication forks or other replication-associated damage, triggering PAR polymerization. Resulting negatively charged PAR polymers may protect stalled replication forks, by repelling proteins that normally would process replication forks (e.g., resolvases), until the replication fork can be restored spontaneously when dNTPs or other co-factors become available. Alternatively, PAR polymers or PARP may attract proteins to resolve the replication block by other means. (iii) In absence of PARP activity, HR may be used as an alternative pathway to repair stalled replication forks. This compensatory model explains the increased level of HR and RAD51 foci found in PARP deficient cells³⁻⁵ and higher PARP activity found in HR deficient cells (i.e. V-C8). Spontaneous replication blocks/lesions are only lethal in the absence of both PARP and HR.

[0063] **Table 1.** Genotype and origin of cell lines used in this study.

Cell line	Genotype	Defect	Origin	Reference
AA8	Wt	Wt	CHO	[41]
irs1SF	<i>XRCC3</i> ⁻	<i>XRCC3</i> ⁻ , deficient in HR	AA8	[41]
CXR3	<i>XRCC3</i> ⁻ + <i>hXRCC3</i>	Wt	irs1SF	[41]
V79-4	Wt	Wt	V79	[40]
irs1	<i>XRCC2</i> ⁻	<i>XRCC2</i> ⁻ , deficient in HR	V79-4	[40]
irs1X2.2	<i>XRCC2</i> ⁻ + <i>hXRCC2</i>	Wt	irs1	[40]
V79-Z	Wt	Wt	V79 [42]	
VC8	<i>BRCA2</i> ⁻	<i>BRCA2</i> ⁻ , deficient in HR	V79-Z	[42]
VC8#13	<i>BRCA2</i> ⁻ + <i>hBRCA2</i>	Wt	VC8	[42]
VC8+B2	<i>BRCA2</i> ⁻ + <i>hBRCA2</i>	Wt	VC8	[42]

REFERENCES:

[0064]

- [1] A.R. Venkiteswaran Cancer susceptibility and the functions of BRCA1 and BRCA2, Cell 108 (2002) 171-182.
- [2] C. Lundin, K. Erixon, C. Amaudeau, N. Schultz, D. Jenssen, M. Meuth and T. Helleday Different roles for non-homologous end joining and homologous recombination following replication arrest in mammalian cells, Mol Cell Biol 22 (2002) 5869-5878.
- [3] D. D'Amours, S. Desnoyers, I. D'Silva and G.G. Poirier Poly(ADP-ribose)ylation reactions in the regulation of nuclear functions, Biochem J 342 (1999) 249-268.
- [4] Z. Herceg and Z.Q. Wang Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death, Mutat Res 477 (2001) 97-110.
- [5] T. Lindahl, M.S. Satoh, G.G. Poirier and A. Klungland Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks, Trends Biochem Sci 20 (1995) 405-411.
- [6] M.S. Satoh and T. Lindahl Role of poly(ADP-ribose) formation in DNA repair, Nature 356 (1992) 356-358.
- [7] S. Shall and G. de Murcia Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?, Mutat Res 460 (2000) 1-15.
- [8] Z.Q. Wang, L. Stingl, C. Morrison, M. Jantsch, M. Los, K. Schulze-Osthoff and E.F. Wagner PARP is important

EP 1 649 017 B2

for genomic stability but dispensable in apoptosis, *Genes Dev* 11 (1997) 2347-2358.

[9] C.M. Simbulan-Rosenthal, B.R. Haddad, D.S. Rosenthal, Z. Weaver, A. Coleman, R. Luo, H.M. Young, Z.Q. Wang, T. Ried and M.E. Smulson Chromosomal aberrations in PARP(-/-) mice: genome stabilization in immortalized cells by reintroduction of poly(ADP-ribose) polymerase cDNA, *Proc Natl Acad Sci U S A* 96 (1999) 13191-13196.

[10] J.M. de Murcia, C. Niedergang, C. Trucco, M. Ricoul, B. Dutrillaux, M. Mark, F.J. Oliver, M. Masson, A. Dierich, M. LeMeur, C. Walzinger, P. Chambon and G. de Murcia Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells, *Proc Natl Acad Sci U S A* 94 (1997) 7303-7307.

[11] F. d'Adda di Fagagna, M.P. Hande, W.M. Tong, P.M. Lansdorp, Z.Q. Wang and S.P. Jackson Functions of poly(ADP-ribose) polymerase in controlling telomere length and chromosomal stability, *Nat Genet* 23 (1999) 76-80.

[12] E. Samper, F.A. Goytisolo, J. Menissier-de Murcia, E. Gonzalez-Suarez, J.C. Cigudosa, G. de Murcia and M.A. Blasco Normal telomere length and chromosomal end capping in poly(ADP-ribose) polymerase-deficient mice and primary cells despite increased chromosomal instability, *J Cell Biol* 154 (2001) 49-60.

[13] C. Morrison, G.C. Smith, L. Stingl, S.P. Jackson, E.F. Wagner and Z.Q. Wang Genetic interaction between PARP and DNA-PK in V(D)J recombination and tumorigenesis, *Nat Genet* 17 (1997) 479-482.

[14] V. Schreiber, D. Hunting, C. Trucco, B. Gowans, D. Grunwald, G. De Murcia and J.M. De Murcia A dominant-negative mutant of human poly(ADP-ribose) polymerase affects cell recovery, apoptosis, and sister chromatid exchange following DNA damage, *Proc Natl Acad Sci U S A* 92 (1995) 4753-4757.

[15] J.H. Kupper, M. Muller and A. Burkle Trans-dominant inhibition of poly(ADP-ribosyl)ation potentiates carcinogen induced gene amplification in SV40-transformed Chinese hamster cells, *Cancer Res* 56 (1996) 2715-2717.

[16] J. Magnusson and C. Ramel Inhibitor of poly(ADP-ribose)transferase potentiates the recombinogenic but not the mutagenic action of alkylating agents in somatic cells in vivo in *Drosophila melanogaster*, *Mutagenesis* 5 (1990) 511-514.

[17] A.S. Waldman and B.C. Waldman Stimulation of intrachromosomal homologous recombination in mammalian cells by an inhibitor of poly(ADP-ribosylation), *Nucleic Acids Res* 19 (1991) 5943-5947.

[18] A. Semionov, D. Cournoyer and T.Y. Chow Inhibition of poly(ADP-ribose)polymerase stimulates extrachromosomal homologous recombination in mouse Ltk-fibroblasts, *Nucleic Acids Res* 27 (1999) 4526-4531.

[19] F. Dantzer, V. Schreiber, C. Niedergang, C. Trucco, E. Flatter, G. De La Rubia, J. Oliver, V. Rolli, J. Menissier-de Murcia and G. de Murcia Involvement of poly(ADP-ribose) polymerase in base excision repair, *Biochimie* 81 (1999) 69-75.

[20] F. Dantzer, G. de La Rubia, J. Menissier-De Murcia, Z. Hostomsky, G. de Murcia and V. Schreiber Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1, *Biochemistry* 39 (2000) 7559-7569.

[21] L. Tentori, I. Portarena and G. Graziani Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors, *Pharmacol Res* 45 (2002) 73-85.

[22] T. Lindahl and R.D. Wood Quality control by DNA repair, *Science* 286 (1999) 1897-1905.

[23] K.W. Caldecott DNA single-strand break repair and spinocerebellar ataxia, *Cell* 112 (2003) 7-10.

[24] D. D'Amours and S.P. Jackson The Mre11 complex: at the crossroads of dna repair and checkpoint signalling, *Nat Rev Mol Cell Biol* 3 (2002) 317-327.

[25] A.D. D'Andrea and M. Grompe The Fanconi anaemia/BRCA pathway, *Nat Rev Cancer* 3 (2003) 23-34.

[26] S.P. Jackson Sensing and repairing DNA double-strand breaks, *Carcinogenesis* 23 (2002) 687-696.

[27] R. Kanaar, J.H. Hoeijmakers and D.C. van Gent Molecular mechanisms of DNA double strand break repair, *Trends Cell Biol* 8 (1998) 483-489.

[28] D.C. van Gent, J.H. Hoeijmakers and R. Kanaar Chromosomal stability and the DNA double-stranded break connection, *Nat Rev Genet* 2 (2001) 196-206.

[29] S.L. Neuhausen and E.A. Ostrander Mutation testing of early-onset breast cancer genes BRCA1 and BRCA2, *Genet Test* 1 (1997) 75-83.

[30] G. Kuperstein, W.D. Foulkes, P. Ghadirian, J. Hakimi and S.A. Narod A rapid fluorescent multiplexed-PCR analysis (FMPPA) for founder mutations in the BRCA1 and BRCA2 genes, *Clin Genet* 57 (2000) 213-220.

[31] A. Chiarugi Poly(ADP-ribose) polymerase: killer or conspirator? The 'suicide hypothesis' revisited, *Trends Pharmacol Sci* 23 (2002) 122-129.

[32] C.R. Calabrese, M.A. Batey, H.D. Thomas, B.W. Durkacz, L.Z. Wang, S. Kyle, D. Skaltitzky, J. Li, C. Zhang, T. Boritzki, K. Maegley, A.H. Calvert, Z. Hostomsky, D.R. Newell and N.J. Curtin Identification of Potent Nontoxic Poly(ADP-Ribose) Polymerase-1 Inhibitors: Chemopotential and Pharmacological Studies, *Clin Cancer Res* 9 (2003) 2711-2718.

[33] D. Ferraris, Y.S. Ko, T. Pahutski, R.P. Ficco, L. Serdyuk, C. Alemu, C. Bradford, T. Chiou, R. Hoover, S. Huang, S. Lautar, S. Liang, Q. Lin, M.X. Lu, M. Mooney, L. Morgan, Y. Qian, S. Tran, L.R. Williams, Q.Y. Wu, J. Zhang, Y. Zou and V. Kalish Design and synthesis of poly ADP-ribose polymerase-1 inhibitors. 2. Biological evaluation of aza-5[H]-phenanthridin-6-ones as potent, aqueous-soluble compounds for the treatment of ischemic injuries, *J Med Chem* 46 (2003) 3138-3151.

EP 1 649 017 B2

- [34] K.J. Dillon, G.C. Smith and N.M. Martin A FlashPlate assay for the identification of PARP-1 inhibitors, *J Biomol Screen* 8 (2003) 347-352.
- [35] A.J. Pierce, R.D. Johnson, L.H. Thompson and M. Jasin XRCC3 promotes homology-directed repair of DNA damage in mammalian cells, *Genes Dev* 13 (1999) 2633-2638.
- 5 [36] R.D. Johnson, N. Liu and M. Jasin Mammalian XRCC2 promotes the repair of DNA double-strand breaks by homologous recombination, *Nature* 401 (1999) 397-399.
- [37] G.M. Shah, D. Poirier, S. Desnoyers, S. Saint-Martin, J.C. Hoflack, P. Rong, M. ApSimon, J.B. Kirkland and G.G. Poirier Complete inhibition of poly(ADP-ribose) polymerase activity prevents the recovery of C3H10T1/2 cells from oxidative stress, *Biochim Biophys Acta* 1312 (1996) 1-7.
- 10 [38] R.J. Griffin, S. Srinivasan, K. Bowman, A.H. Calvert, N.J. Curtin, D.R. Newell, L.C. Pemberton and B.T. Golding Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP), *J Med Chem* 41 (1998) 5247-5256.
- [39] S. Boulton, L.C. Pemberton, J.K. Porteous, N.J. Curtin, R.J. Griffin, B.T. Golding and B.W. Durkacz Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors, *Br J Cancer* 72 (1995) 849-856.
- 15 [40] C.S. Griffin, P.J. Simpson, C.R. Wilson and J. Thacker Mammalian recombination-repair genes XRCC2 and XRCC3 promote correct chromosome segregation, *Nat Cell Biol* 2 (2000) 757-761.
- [41] R.S. Tebbs, Y. Zhao, J.D. Tucker, J.B. Scheerer, M.J. Siciliano, M. Hwang, N. Liu, R.J. Legerski and L.H. Thompson Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene, *Proc Natl Acad Sci U S A* 92 (1995) 6354-6358.
- 20 [42] M. Kraakman-van der Zwet, W.J. Overkamp, R.E. van Lange, J. Essers, A. van Duijn-Goedhart, I. Wiggers, S. Swaminathan, P.P. van Buul, A. Errami, R.T. Tan, N.G. Jaspers, S.K. Sharan, R. Kanaar and M.Z. Zdzienicka Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions, *Mol Cell Biol* 22 (2002) 669-679.
- 25 [43] J. Nakamura, S. Asakura, S.D. Hester, G. de Murcia, K.W. Caldecott and J.A. Swenberg Quantitation of intracellular NAD(P)H can monitor an imbalance of DNA single strand break repair in base excision repair deficient cells in real time, *Nucleic Acids Res* 31 (2003) e104.
- [44] H. Halldorsson, D.A. Gray and S. Shall Poly (ADP-ribose) polymerase activity in nucleotide permeable cells, *FEBS Lett* 85 (1978) 349-352.
- 30 [45] K. Grube, J.H. Kupper and A. Burkle Direct stimulation of poly(ADP ribose) polymerase in permeabilized cells by double-stranded DNA oligomers, *Anal Biochem* 193 (1991) 236-239.
- [46] C. Lundin, N. Schultz, C. Arnaudeau, A. Mohindra, L.T. Hansen and T. Helleday RAD51 is Involved in Repair of Damage Associated with DNA Replication in Mammalian Cells, *J Mol Biol* 328 (2003) 521-535.
- 35 [47] Schreider et al., *Journal of Biological Chemistry* 277: 23028-23036 (2002).

P A T E N T K R A V

1. Anvendelse af en poly-(ADP-ribose)-polymerase-1-(PARP-1)-inhibitor i fremstillingen af et lægemiddel til behandling af cancerceller defekte i homolog rekombination (HR) hos et menneske;
 - 5 hvor cancercellerne har en defekt i et gen valgt blandt gruppen bestående af XRCC1, CTPS, RPA, RPA1, RPA2, RPA3, XPD, ERCC1, XPF, MMS19, RAD51, RAD51B, RAD51C, RAD51D, DMC1, XRCC2, XRCC3, BRCA1, BRCA2, RAD52, RAD54, RAD50, MRE11, NBS1, WRN, BLM, Ku70, Ku80, ATM, ATR, chk1, chk2, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, RAD1, RAD9, FEN-1, Mus81, Emel, DDS1 og BARD.
- 10 2. Anvendelse ifølge krav 1, hvor PARP-1 inhibitoren er et RNAi-molekyle specifikt mod et PARP-gen.
 3. Anvendelse ifølge krav 2, hvor RNAi molekylet er afledt fra et nukleinsyre-molekyle omfattende en nukleinsyresekvens valgt fra gruppen bestående af:
 - a) en nukleinsyresekvens som repræsenteret ved sekvensen ifølge figur 9, eller et
 - 15 fragment deraf;
 - b) en nukleinsyresekvens, som hybridiserer til nukleinsyresekvensen ifølge figur 9 og koder for et gen af PARP; eller
 - c) en nukleinsyresekvens, som omfatter sekvenser, der er degenereret som et resultat af de genetiske koder af nukleinsyresekvenserne defineret i (a) og (b).
- 20 4. Anvendelse ifølge krav 2 eller krav 3, hvor RNAi-molekylet omfatter nukleinsyresekvenserne aaa agc cau ggu gga gua uga.
5. Anvendelse ifølge et hvilket som helst af de foregående krav, hvor cancercellerne defekte i HR delvis mangler HR.
6. Anvendelse ifølge et hvilket som helst af krav 1 til 4, hvor cancercellerne defekte i
- 25 HR fuldstændig mangler HR.
7. Anvendelse ifølge et hvilket som helst af de foregående krav, hvor defekten er en mutation i genet.
8. Anvendelse ifølge et hvilket som helst af de foregående krav, hvor defekten er fravær af genet.
- 30 9. Anvendelse ifølge et hvilket som helst af de foregående krav, hvor defekten er i ekspressionen af genet.
10. Anvendelse ifølge et hvilket som helst af de foregående krav, hvor cancercellerne, der skal behandles er valgt fra gruppen bestående af lunge-, colon-, pancreatiske, gastriske, ovarie-, cervicale-, bryst- og prostata-cancerceller.
- 35 11. Anvendelse ifølge et hvilket som helst af de foregående krav, hvor cancercellerne, der skal behandles er gen-bundne arvelige cancerceller.
12. Anvendelse ifølge krav 11, hvor cancercellerne, der skal behandles, er brystcancerceller.
13. Anvendelse ifølge et hvilket som helst af de foregående krav, hvor cancercellerne, der skal behandles, er defekte i BRCA1-ekspression.
- 40

14. Anvendelse ifølge et hvilket som helst af de foregående krav, hvor cancercellerne, der skal behandles, er defekte i BRCA2-ekspression.

15. Anvendelse ifølge krav 13 eller 14, hvor cancercellerne delvis mangler BRCA1- og/eller BRCA2-ekspression.

5 16. Anvendelse ifølge krav 13 eller 14, hvor cancercellerne fuldstændig mangler BRCA1 og/eller BRCA2-ekspression.

17. Poly-(ADP-ribose)-polymerase-1-(PARP-1)-inhibitor til anvendelse i behandling af cancerceller defekte i homolog rekombination (HR) hos et menneske;

10 hvor cancercellerne har en defekt i et gen valgt fra gruppen bestående af XRCC1, CTPS, RPA, RPA1, RPA2, RPA3, XPD, ERCC1, XPF, MMS19, RAD51, RAD51B, RAD51C, RAD51D, DMC1, XRCC2, XRCC3, BRCA1, BRCA2, RAD52, RAD54, RAD50, MRE11, NBS1, WRN, BLM, Ku70, Ku80, ATM, ATR, chk1, chk2, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, RAD1, RAD9, FEN-1, Mus81, Emel, DDS1 og BARD.

15 18. PARP-1 inhibitor til anvendelse ifølge krav 17, hvor cancercellerne defekte i HR delvist mangler HR.

19. PARP-1 inhibitor til anvendelse ifølge krav 17, hvor cancercellerne defekte i HR fuldstændig mangler HR.

20 20. PARP-1 inhibitor til anvendelse ifølge et hvilket som helst af krav 17 til 19, hvor cancercellerne, der skal behandles er valgt fra gruppen bestående af lunge-, colon-, pancreatiske, gastriske, ovarie-, cervicale-, bryst- og prostata-cancer celler.

21. PARP-1-inhibitor til anvendelse ifølge et hvilket som helst af krav 17 til 20, hvor cancercellerne, der skal behandles, er gen-bundne arvelige cancer celler.

22. PARP-1 inhibitor til anvendelse ifølge krav 21, hvor cancercellerne, der skal behandles, er brystcancer celler.

25 23. PARP-1 inhibitor til anvendelse ifølge et hvilket som helst af krav 17 til 22, hvor cancercellerne, der skal behandles, er defekte i BRCA1- eller BRCA2-ekspression.

Figure 1.




Figure 2.




Figure 3




Figure 4












Figure 5A







Flg. 6




Fig. 7




FIGURE 9

1 cgcccgccca gccccggggg cagggaaagc cttaaattacg gaattaccgc gagcaaggag
 61 cgcggaatcg gggagcggtcc ggagctagct ggatcctcta ggcaggatgg tgaigggaat
 121 ctttgcaaat tgtatcttct gtttgaaagt gaagtactta cctcagcagc agaagaaaaa
 181 gctacaaact gacattaagg aaaatggcgg aaagttttcc ttttcgttaa atcttcagt
 241 cacacataata atcttagata atgctgatgt tctgagtcag taccaactga attctatcca
 301 aaagaaccac gttcatattg caaaccaga tttatatgg aaatctatca gagaaaagag
 361 actcttggat gtaaagaatt atgatccta taagccccg gacatcacac caccicctga
 421 tcagaaggcg agcagttctg aagtgaaac agaaggctta tggccggaca gtgccacaga
 481 ggaggaagac actgtggaac tcactgagtt tggtagcag aatgttgaaa ttcttcaict
 541 tctcaagat ttgaagttg caaaataaa caccitggag aaagtgggaa tggagggagg
 601 ccaggaagct gtgggtggg agcttcagt ttcggggac tccaggagact gtccttct
 661 gatctctca cacttctcc tggatgatgg catggagact agaagacagt ttgctataaa
 721 gaaaacctct gaagatgcaa gtgaatactt tgaataaac attgaagaac tgaagaaaca
 781 aggatticta ctaagagaac attcacacc tgaagcaacc caattagcat ctgaacaatt
 841 gcaagcattg cttttggagg aagtcataa ttcaagcact ctgagccaag aggtgagcga
 901 tttagtagag atgatttggg cagaggccct gggccacctg gaacacatgc ttccaagcc
 961 agtgaacagg attagcctca acgatgtgag caaggcagag gggatttccc ttctagtaaa
 1021 ggagcactg aaaaatggag aaacagcaga gcaattgcaa aagatgatga cagagtitta
 1081 cagactgata cctcacaag gcacaatgcc caaagaagtg aacctgggac tattggctaa
 1141 gaaagcagac ctctgccagc taataagaga catggttaat gtctgtgaaa ctaattgtc
 1201 caaacccaac ccacatccc tggccaaata ccgagcttg aggtgcaaaa ttgagcatg
 1261 tgaacagaat actgaagaat ttctcagggt tagaaaagag gttttgcaga atcatcacag
 1321 taagagccca gtggatgtct tgcagataat tagagttggc agagtgaatg aaaccacaga
 1381 gttttgagc aaacttggta atgtgagggc ctgttgcat ggttctctg taaaaacat
 1441 cgtgggaatc ttgtgtcag ggttgcctt acccaaagta gtggaagatc gtgggtgtca
 1501 aagaacagac gtcggaaacc ttggaagtgg gatttattc agtgattcgc tcagtacaag
 1561 tatcaagtac tcacaccgg gagagacaga tggcaccaga ctctgtcta ttgtgacgt
 1621 agccctcggg aagtgtatgg acttacatga gaaggacttt tcttaactg aagcaccacc
 1681 aggtacgac agtgtgatg gagtttaca aacagcctct gtcaccacag actttgagga
 1741 tgalgaattt gttgtctata aaaccaatca ggttaaaatg aaatatatta ttaaatttc
 1801 catgcctgga gatcagataa aggactttca tcttagtgat catactgaat tagaggaata
 1861 cagacctgag tttcaaat tttcaaggt tgaagattac cagttaccag atgcaaaaac
 1921 ttccagcagc accaaggccg gcctccagga tgcctcigg aacttggttc ctctggagga
 1981 tgtccacatc aaaggagaa tcatagacac ttagccag gtcattgtt ttacagata
 2041 cacaataaaa agtcacgtgc ccattgagc aaaatatatc ttcccttgg atgacaaggc
 2101 cgctgtgtgt ggcttgaag ccttcatcaa tgggaagcac atagttggag agattaaga
 2161 gaaggaagaa gccagcaag agtacclaga agccgtgacc cagggccatg gcgcttacct
 2221 galgagtcag galgtccgg acgttttacc tgaagtgtt ggaaacttac cccctaaggc
 2281 taaggttctt ataaaaata cctacatcac agaactcagc atcctgggca cgttgggt
 2341 cttttcatg cccgccacc tagcaccctg gcaacaggac aaggcttga atgaaaacct
 2401 tcaggataca gtagagaaga ttgtataaa agaaatagga acaaaagcaa gttctcttt
 2461 gactatgtct attgagatgc cgtacgtgat tgaattcatt ttacgtgata ctcatgaact
 2521 gaaacaaaag cgcacagact gcaagctgt cattagcacc atggaaggca gtcctttaga
 2581 cagcagtggg tttctctcc acatcggtt gtctgtgcc tatctccaa gaatgtgggt
 2641 tgaaaaacat ccagaaaaag aaagcgaggc ttgcatgct gtcttcaac ccgatctga
 2701 tctgaccctc cctgacctag ccaatgagag cgaagtgatt attgtcttg actgtccag
 2761 ttcatggag ggtgtgacat tcttgaagc caaggaaac gccttgcag cgctgtctt

2821 ggtgggtgag aagcagaaag taaatattat ccagttcggc acaggttaca aggagctatt
 2881 ttctatctct aagcatatca caagcaatac cgcggcagca gagttcatca tgtctgccac
 2941 acctaccatg gggaacacag acttctggaa aacactccga tatcttagct tatgtaccac
 3001 tgctcgaggg tcacggaaca tcttctgggt gtctgatggg cacttccagg atgagagcct
 3061 gacattacag ctctgtgaaga ggagccgccc gcacaccagg ttattgcct gcggtatcgg
 3121 ttctacagca aatcgtcacg tcttaaggat ttgtcccag tgtggcgccg gattattiga
 3181 atattttaat gcaaaatcca agcatagtgt gagaaaacag atagaagacc aaatgaccag
 3241 gctatgttct ccgagttgcc actctgtctc cgtcaaatgg cagcaactca atccagatgc
 3301 gcccagggcc ctgcaggccc cagcccagggt gccatccttg ttctgcaatg atcgactcct
 3361 tgtctatgga ttcattcttc actgcacaca ggcaactctg tgtgactaa tcaagagaa
 3421 agaattttgt acaatggtgt cgactactga gcttcagaag acaactggaa ctatgatcca
 3481 caagctggca gcccagagctc taatcagaga ttatgaagat ggcaattctc acgaaaatga
 3541 aaccagtcac gagatgaaaa aacaaacctt gaaatctctg attattaaac tcagtaaaga
 3601 aaactctctc ataacacaat ttacaagctt tgtggcagtt gagaaaaggg atgagaatga
 3661 gtcacctttt cctgatattc caaaagtctc tgaactatt gccaaagaag atgtagactt
 3721 cctgccctac atgagctggc aggggggaacc ccaagaagcc gtcaggaacc agtctctttt
 3781 agcatcctct gagtggccag aattacgttt atccaaacga aaacatagga aaattccatt
 3841 ttccaaaaga aaaatggaat tatctcagcc agaagtctt gaagattttg aagaggatgc
 3901 cttaggtgta ctaccagctt tcacatcaaa ttggaacgt ggacgtgtgg aaaagctatt
 3961 ggatttaagt tggacagagt catgtaaac aacagcaact gaaccactat ttaagaaagt
 4021 cagtccatgg gaaacatcta ctctagctt ttctctatt ttggctccgg ccgttggttc
 4081 ctatcttacc ccgactacce gcgtcacag tctgtctcc ttgtctttg cctcatatcg
 4141 tcaggtagct agtttcggtt cagctgtctc tccagacag ttgatgcac ctcaattcag
 4201 ccaaggccct gtgcttgga cttgtgtga ctggatccca cagtcggcgt cttgtcccac
 4261 aggacctccc cagaaccac ctctgcacc ctatgtggc attgtttttt caggagctc
 4321 attagctct gcacagctc ctccactgca acatcttga ggctttacta ccaggccttc
 4381 tgctggcacc tcccagagc tggattctc ccagcttcat ttctctctc ctacagacc
 4441 tgatcccatc agaggttttg ggtcttatca tccctctgt tactctcctt ttcaattca
 4501 acctccgca gcctcttga ctgccaacct taggctgcca atggcctctg cttacctga
 4561 ggctctttgc agtcagctcc ggactacccc agtagatctc tgtctctag aagaatcagt
 4621 aggcagctc gaaggaagtc gatgtcctgt cttgtcttt caaagtctg acacagaaag
 4681 tgatgagcta tcagaagtac tcaagacag ctgctttta caaataaaat gtgatacaaa
 4741 agatgacagt atccctgtct ttctggaagt aaaagaagag gatgaaatag tgtgcacaca
 4801 acactggcag gatgctgtgc cttggacaga actcctcagt ctacagacag aggatggctt
 4861 ctggaacctt acaccagaac tgggacttat attaaatctt aatacaaatg gtttcacag
 4921 cttcttaaa caaaaaggca ttcaatctct aggtgtaaaa ggaagagaat gtctcctgga
 4981 cctaattgcc acaatgcig tactacagtt tattgcacc aggttggaag aagagggaaat
 5041 agtgttcaaa tcactgatga aaatggatga ccttctatt tccaggaata ttccctgggc
 5101 ttttaggca ataaagcaag caagtgaatg ggtaagaaga actgaaggac agtaccatc
 5161 tatctgcca cggttgaaac tggggaacga ctgggactct gccaccaagc agttgtggg
 5221 actccagccc ataaagcactg tgtccctctc tcalagagtc ctccattaca gtcaaggcta
 5281 agtcaaatga aactgaattt taaactttt gcattgtct atgtagaaaa taatcaaatg
 5341 ataatagata cttataatga aacttcatta aggtttcatt cagtgtagca attactgtc
 5401 ttaaaaaatta agtggaaaga gaattacttt aatcaactaa caagcaataa taaaatgaaa
 5461 cttaaaat

Figure 10

1 ctagaattca gcggccgctg aattctaggc ggcgcggcgg cgacggagca ccggcggcgg
 61 cagggcgaga gcaltaaatg aaagcaaaag agttaataat ggcaacacgg ctccagaaga
 121 ctctcccct gccaaagaaa ctctagatg ccagagacag gattcgaaaa agatgcctgt
 181 ggctggagga aaagctaata aggacaggac agaagacaag caagatggta tgcaggaag
 241 gtcatgggcc agcaaaaggg tctctgaatc tctgaaggcc ttgctgtta agggcaaaag
 301 tctgtggac ccagagtgt cagccaaggt ggggaaggct catgtgtatt gtgaaggaaa
 361 tgatgtctat gatgtcatgc taaatcagac caatctccag ttcaacaaca acaagtacta
 421 tctgattcag ctattagaag atgatgccc gaggaacttc agtgtttgga tgagatgggg
 481 ccgagttggg aaaatgggac agcacagcct ggtggcttgt tcaggcaatc tcaacaaggc
 541 caaggaaatc tticagaaga aattccctga caaacgaaa aacaattggg aagatcgaga
 601 aaagtttgag aaggtgcctg gaaaatatga tatgtacag atggactatg ccaccaatac
 661 tcaggatgaa gaggaacaa aaaaagagga atctcttaa tctccctga agccagagtc
 721 acagctagat ctccgggtac aggagttaat aaagttgatc tgtaatttc aggccatgga
 781 agaatgatg atggaaatga agtataatac caagaagcc ccacttgga agctgacagt
 841 ggcacaaatc aaggcaggt accagtcct taagaagatt gaggattgta ttgggctgg
 901 ccagcatgga cgagctctca tggaaagcat caatgaatc tacaccagga ttccgatga
 961 cttggactc cgtactctc cactaatccg gacacagaag gaactgtcag aaaaaataca
 1021 attactagag gcttgggag acattgaaat tgctattaag ctggtgaaa cagagctaca
 1081 aagcccagaa caccattgg accaacta tagaaacta catgtgcct tgcgccccct
 1141 tgaccatgaa agttacagt tcaaagtgt tcccagtc ctacaatca cccatgctc
 1201 cacacacagc gactatacca tgacctgtc ggattgtt gaagtggaga aggatgggta
 1261 gaaagaagcc ttcagagagg acctcataa caggatgct ctatggcatg gtccaggat
 1321 gagtaactgg gtgggaatct tgagccatgg gcttcgaat gccaccctg aagctccat
 1381 cacaggttac atgttggga aaggaatca cttgtgtac atgtctcca agagtccaa
 1441 ttactgctt gccctcgcc taaagaatac aggactgct ctctatcag aggtagctc
 1501 aggtcagtgt aatgaactac tagaggccaa tctaaggcc gaaggattgc ttcaaggtaa
 1561 acatagcacc aaggggctgg gcaagatggc tccagttct gccacttcg tcaccctgaa
 1621 tgggagtaca gtgccattag gaccagcaag tgacacagga attctgaatc cagatggta
 1681 taccctcaac tacaatgaat atattgtata taacccaac caggtccgta tgcggtacct
 1741 tttaaagggt cagttaatt tcttcagct gtggtgaatg tgaactta ataaaccaga
 1801 gatctgatc tcaagcaaga aaataagcag tgtgtactt gtgaatttt gatatttta
 1861 tgaataaaa actgtacagg tctaaaaaa aaaaaaaaa aaaaaaaaa

//

Figure 11

```

1 tgggactggt cgcctgactc ggccctgccc agcctctgct tcacccact ggtggccaaa
61 tagccgatgt ctaatcccc acacaagctc atccccggcc tctgggattg ttgggaattc
121 tctcccta atcagcctga ggctcatgga gagttgctag acctgggact gccctgggag
181 gcgcacacaa ccaggccggg tggcagccag gacctctccc atgtccctgc ttctctggc
241 catggctcca aagccgaagc cctgggtaca gactgagggc cctgagaaga agaaggcccg
301 gcaggcagga agggaggagg accccttccg ctccaccgt gaggcctca agccataacc
361 cgcagagaag cgcataatcc gcgtggatcc aacatgtcca ctacagcga accccgggac
421 ccagggtgat gaggactaca actgcacct gaaccagacc aacatcgaga acaacaaca
481 caagttctac atcatccagc tgtccaaga cagcaaccgc ttctcacct gctggaaccg
541 ctggggccgt gtgggagagg tggccagtc aaagatcaac cacttcaca ggctagaaga
601 tgcaagaag gacttgaga agaaattcg ggaaaagacc aagaacaact gggcagagcg
661 ggaccacttt gtgtctacc cgggcaagla cacactatc gaagtacagg cagaggatga
721 ggcccaggaa gctgtggtga aggtggacag aggccagtg aggactgtga ctaagcgggt
781 gcagccctgc tcctggacc cagccacga gaagctcacc actaacatct tcagcaagga
841 gatgtcaag aacaccatgg cctcatgga cctggatgtg aagaagatgc ccctgggaaa
901 gctgagcaag caacagattg cacggggtt cgaggccttg gaggcgttg aggaggccct
961 gaaaggcccc acgatggtg gccaaagcct ggaggagctg tctcacact ttacaccgt
1021 catccgcac aattcggcc acagccagcc cccgccatc aattccctg agcttctga
1081 ggccaagaag gacatgctgc tgggtctggc ggacatcgag ctggccagg ccctgcaggc
1141 agtctctgag caggagaaga cgggtggagg ggtgccacac cccctggacc gagactacca
1201 gcttctcaag tgccagctgc agctgctaga ctctggagca cctgagtaca aggtgataca
1261 gacctacta gaacagactg gcagcaacca caggtgccct acactcaac acatctggaa
1321 agtaaaccaa gaaggggagg aagacagatt ccaggccac tccaaactgg gtaatcgaa
1381 gctgctgtgg catggacca acatggccgt ggtggccgcc atctcacta gtgggtccg
1441 catcatgcca catctggtg ggcgtgttg caagggcac tactttgcct cagagaacag
1501 caagtcagct ggatatgta ttggcatgaa gtgtggggcc caccatgtc gctacatgt
1561 cctgggtgag gtggcccttg gcagagagca ccatatcaac acggacaacc ccagcttgaa
1621 gagccacct cctggcttg acagtgtcat tggccaggc cacaccgagc ctgaltccag
1681 ccaggacact gagttggagc tggatggcca gcaagtgtg gtgcccagg gccagcctgt
1741 gccctgcca gagttcagca gtccacatt ctccagagc gactacctca tctaccagga
1801 gagccagtg cgcctgcgt acctgctgga ggtccaccic tgagtggcc cctgtctccc
1861 cggggtctg caaggctgga ctgtgatct caatcatct gccatctct ggtacccta
1921 taccctct ttttcaag aatacaatc gttgtgtta actatagta ccatgctga
1981 caagatccct gaacttatgc ctctaactg aaatttgtta ttcttgaca catctgcca
2041 gtccctctc tccagccca tggtaaccag catttgactc ttacttgta taagggcagc
2101 tttatagg tccacatgta agtgagatca tgcagtgtt gtcttctgt gccctgctta
2161 ttacactcag cataatgtgc accgggttca cccatgttt cataaatgac aagatttct
2221 cctttaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa

```

Figure 12

```

1  cgaagatggc  ggcgtcgcg  cgctctcagc  atcatcacca  ccatacatca  caacagctcc
61  agcccgcgcc  aggggcttca  ggcgcgcgcg  ccccacctcc  tccccactcc  agccctggcc
121  tggcccccgg  gaccacccca  gcctctccca  cggccagcgg  cctggccccc  ttgcctccc
181  cgcggcacgg  cctagcgctg  ccggaggggg  atggcagtcg  ggatccgccc  gacaggcccc
241  gatccccgga  cccggttgac  ggtaccagct  gtgcagtac  caccagcaca  atctgtaccg
301  tcgcgcgcgc  tcccgctggc  ccagcgggtt  ctacttcata  tgccgctggg  gtgcctccca
361  acccagccgg  cagtggcagt  aacaattcac  cgtcgtccct  tcttccccc  acttcttctt
421  catcttccct  tccatccctc  cctggatcga  gcttggcgga  gagccccgag  gcggccggag
481  ttagcagcac  agcaccactg  gggcctgggg  cagcaggacc  tgggacaggg  gtcccagcag
541  tgagcggggc  cctacgggaa  ctgctggagg  cctgtcgcaa  tggggacgtg  tcccggttaa
601  agaggctggg  ggacgcggca  aacgtaaatg  caaaggacat  ggccggccgg  aagtctcttc
661  cctgcacttt  cgctgcaggt  tttggaagga  aggatgttgt  agaaccacta  ctacagatgg
721  gtgctaattg  ccacgctcgt  gatgatggag  gtctcatccc  gcttcataat  gctgtctctt
781  ttggccatgc  tgagggtgtg  agtctgttat  tgtgccaagg  agctgatcca  aatgccaggg
841  ataactggaa  ctatacact  ctgcatgaag  ctgctattaa  agggaaagtc  gatgtgtgca
901  ttgtgctgct  gcagcacgga  gctgacccaa  acattcgga  cactgatggg  aatcagccc
961  tggacctggc  agatccctca  gcaaaaagct  tccctacagg  tgaatacaga  aaagacgaac
1021  tcttagaagc  tgctaggagt  ggtaatgaag  aaaaactaat  ggcttactag  actcctctaa
1081  atgtgaattg  ccatgcaagt  gatggcgaa  agtcgactcc  ttacatcta  gcagcgggct
1141  acaacagagt  tgaatagtt  cagcttcttc  ttcagcatgg  tgctgatgtt  catgcaaaag
1201  acaagggtgg  acttgtgctt  ctctcataat  catgttcata  tggacattat  gaagtccacg
1261  aactgctact  aaagcatgga  gcttgtgtta  atgccatgga  tctctggcag  ttactccac
1321  tgacagaggg  tgcttccaag  aaccgtgtag  aagtctgctc  ttgttacttt  agccatggcg
1381  ctgactcctc  gttagtcaac  tgcctatggc  aaagtgtgtg  ggatatggct  ccaactccgg
1441  agcttaggga  gagattgact  tatgaattta  aaggtcattc  ttactacaa  gcagccagag
1501  aagcagactt  agctaaagtt  aaaaaaacac  tcgctctgga  aatcattaat  ttcaaacac
1561  cgcagcttca  tgaacacaga  ctgcactgtg  ctgtggcctc  tctgcacccc  aaacgtaaac
1621  aagtgcacga  attgttactt  agaaaaggag  caaatgttaa  tgaaaaaat  aaagatttca
1681  tgactccctc  gcatgttgca  gccgaaagag  cccataatga  tgctatggaa  gttctgcata
1741  agcatggcgc  caagatgaat  gcactggaca  ccttgggtca  gactgctttg  catagagccg
1801  ccttagcagg  ccacctgcag  acctgcccgc  tcctgctgag  ttacggctct  gacccctcca
1861  tcatctcctt  acaaggcttc  acagcagcac  agatgggcaa  tgaagcagtc  cagcagattc
1921  tgagtgtgag  ttaeggtctt  gacccctcca  tcctctcctt  acaaggcttc  acagcagcac
1981  agatgggcaa  tgaagcagtg  cagcagattc  tgagtgtgca  tctgtagata  gtgatcattc
2041  tacttcagcc  ttaatgggtg  tcttgagacg  ggaagattta  gaaggaaatc  tatccagcat
2101  gtcttcactg  tcaacatgaa  gagtacacct  atacgtactt  ctgatgttga  ttatcgactc
2161  ttagaggcat  ctaaagctgg  agacttgga  actgtgaagc  aactttgcag  ctctcaaaat
2221  gtgaattgta  gagacttaga  gggccggcat  tccacgcctc  tacacttcgc  agcaggctae
2281  aacagagtac  acctatacgt  acttctgatg  ttgattatcg  actcttagag  gcacttaaa
2341  ctggagactt  ggaactgtg  aagcaacttt  gcagctctca  aaatgtgaat  tgtagagact
2401  tagaggccg  gcattccacg  ccttacact  tccgacagag  ctacaaccgc  gtgtctgttg
2461  tagagtacct  gctacaccac  ggtgccgatg  tccatgcaa  agacaagggt  ggcctgggtc
2521  ccttcataaa  tgcctgttca  tatggacact  atgagggtgg  tgagctttta  tgaaaggcatg
2581  gggcttctgt  caatgtggcg  gacttatgga  aatttaccct  tctccatgaa  gcagcagcta
2641  aaggaaagta  tgaaatctgc  aagctccttt  taaaacatgg  agcagatcca  actaaaaga
2701  acagagatgg  aaatacacct  ttggatttgg  taaagggaag  agacacagat  attcaggact
2761  tactgaaagg  ggatgtgtgt  ttgttggtat  ctgccaagaa  gggctgcctg  gcaagagtg
2821  agaagctctg  taccacagag  aatatcaact  gcagagacac  ccagggcaga  aattcaaccc
2881  ctctgcacct  ggcagcagcg  tataataacc  tggaggtagc  tgaatatctt  ctagagcatg
2941  gagctgatgt  taatgccag  gacaagggtg  gtttaattcc  tcttcataat  gcggcatctt
3001  atgggcatgt  tgacatagcg  gctttattga  taaaatacaa  cactgtgtga  aatgcaacag
3061  ataagtgggc  gtttactccc  ctccatgaag  cagcccagaa  aggaaggacg  cagctgtgct
3121  cctcctcct  agcgcattgt  gcagacccca  ccatgaagaa  ccagggaagg  cagacgcctc
3181  tggatctggc  aacagctgac  gatatacag  ctttgctgat  agatggccat  ccccgagagg
3241  ccttacctac  ctgttttaaa  cctcaggcta  ctgtagttag  tgcctctctg  atctcaccag
3301  catccacccc  ctctgccttc  tcggctgcca  gcagcataga  caacctcact  ggccttttag
3361  cagagtggc  cgtaggagga  gcctccaatg  caggggatgg  cgcgcgggga  acagaaagg
3421  aggaaggaga  agttgctgg  cttagcatga  atatcagcca  atttctaaaa  agccttggcc
3481  ttgaacacct  tcgggatatc  tttgaaacag  aacagattac  actagatgtg  ttggtgata
3541  tgggtcatga  agagtggaaa  gaaataggca  tcaatgcata  tgggcacccg  cacaatttaa
3601  tcaaaaggag  agaaagactc  ctagggtggc  aacaaggcac  caatccttat  ttgacttttc
3661  actgtgttaa  tcagggaacg  attttgcctg  atcttgcctc  agaagataaa  gaatatcagt
3721  cagtggaaag  agagatgcaa  agtactatcc  gagaacacag  agatgggtgg  aatgctggcg
3781  gcatcttcaa  cagatacaat  gtcattcgaa  ttcaaaaagt  tgcaaccaag  aagttgaggg
3841  agcgggtctg  ccaccgacag  aagggaagtgt  ctgaggagaa  tcacaacccat  cacaatgagc

```

3901 gcatgttggt tcatggttct cctttcatta atgccattat tcataaaggg tttgatgagc
3961 gacatgcata cataggagga atgtttgggg ccgggattta ttttgctgaa aactcctcaa
4021 aaagcaacca atatgtttat ggaattggag gaggaacagg ctgccctaca cacaaggaca
4081 ggtcatgcta tataatgtcac agacaaatgc tcttctgtag agtgaccctt gggaaatcct
4141 ttctgcagtt tagcaccatg aaaaatggccc acgcgcctcc agggcaccac tcagtcattg
4201 gtagaccgag cgtcaatggg ctggcatatg ctgaatatgt catctacaga ggagaacagg
4261 catacccaga gtatcttata acttaccaga tcatgaagcc agaagcccct tcccagaccg
4321 caacagccgc agagcagaag acctagtga tgcctgctgg tgaaggccag atcagatttc
4381 aacctgggac tggattacag aggattgttt ctaataacaa catcaatatt ctagaagtcc
4441 ctgacagcct agaaataagc tgtttgtctt ctataaagca ttgctatagt g

Figure 13

1 cgcgccgcct cgctagccga aacctgccca gccgggtgcc ggccactgcg cagcgccggg
 61 acgacgtcac gtgcgtctcc ggggctggac ggagctggca ggaggggcct tgccagcttc
 121 cgccgcccgc tctttcagg acccgagcgg cggattcgcg ctgcctccgc cgccgcccgg
 181 cagccggggg gcagggagcc cagcgagggg cgccgctggg cgccggccatg ggaactgcgc
 241 ggatccgggt acagcaggga gccaaagcgc ccgggcccctg agcgcgtctt ctccgggggg
 301 cctcgcctc ctgctcgcgg ggccggggct cctgctccgg ttgctggcgc tgtgtctggc
 361 tgtggcggcg gccaggaatc tctgggctg ccgctgcgcc ggccgggggag cggcctgcgc
 421 gagcgccgcg gccgaggccg tggagccggc cgcccgagag ctgttcgagg cgtgccgcaa
 481 cggggagctg gaacgagtca agaggctggt gacgcctgag aaggtgaaca gccgcgacac
 541 ggccgggcagg aaatccaccc cgctgcactt cccgcaggt ttggggcgga aagacgtagt
 601 tgaatatgt cttcagaatg gtgcaaatgt ccaagcacgt gatgatgggg gccattatcc
 661 tctcataat gcatgctctt ttggtcatgc tgaagtagtc aatctcttt tgcgacatgg
 721 tgcagacccc aatgctcgag ataattgaa ttactctct ctccatgaag ctgcaattaa
 781 aggaaagatt gatgtttgca ttgtctgtt acagcatgga gctgagccaa ccatccgaaa
 841 tcagatgga aggacagcat tggatttagc agatccatct gccaaagcag tcttactgg
 901 tgaatataag aaagatgaac tcttagaag tgcaggagt ggcaatgaag aaaaaatgat
 961 ggctctactc acaccattaa atgtcaactg ccacgcaagt gatggcagaa agtcaactcc
 1021 attacattg gcagcaggat ataacagagt aaagattgta cagctgttac tgaacatgg
 1081 agctgatgc catgctaaag ataaaggta tctgttacc ttacacaatg cctgttcta
 1141 tggctattat gaagtaactg aacttttgg caagcatggt gctgtgtaa atgcaatgga
 1201 ctgtggcaa tctactctc tcatgaggc agcttctaag aacaggggtg aagtatgtc
 1261 tcttctcta agttatggtg cagacccaac actgctcaat tgcacaata aaagtctat
 1321 agacttggct cccacaccac agttaaaga aagattagca tatgaattta aagggcactc
 1381 gttgctgcaa gctgcagag aagctgatgt tactcgaatc aaaaaacatc tctcttggg
 1441 aatggtgaat tcaagcatc ctcaaacaca tgaacagca ttgcattgtg ctgctgcac
 1501 tccatctcc aaaaagaaagc aaatatgta actgttgcta agaaaaggag caaacatcaa
 1561 tgaagaaact aaagaattct tgactctct gcacgtggca tctgagaaag ctcataatga
 1621 tgttgttga gtagtggtga aacatgaagc aaaggttaat gctctggata atcttggtca
 1681 gacttctta cacagagctg catattgtg tcatctaca acctgccgcc tactctgag
 1741 ctatgggtgt gatcctaaca ttatccctc tcaggcctt actgctttac agatgggaaa
 1801 tgaatatgta cagcaactcc tcaagaggg tatctatta ggtaattcag aggcagacag
 1861 acaattgctg gaagctgcaa aggttgaga tctgaaact gtaaaaaaac tgtgtactgt
 1921 tcagagtgtc aactgcagag acattgaagg gcgtcagct acaccacttc atttgcagc
 1981 tgggataaac agagtgtccg tgggtgaata tctgtacag catggagctg atgtgcatg
 2041 taaagataaa ggaggccttg tacctttgca caatgcatgt tcttatggac attatgaagt
 2101 tgcagaactt ctgtttaac atggagcagt agttaatgta gctgattat ggaaattac
 2161 acctttacat gaagcagcag caaaaggaaa atatgaaat tgcaaacttc tgcctcagca
 2221 tggtcagac cctacaaaaa aaaacaggga tggaaatact cctttgcatc ttgttaaga
 2281 tggagataca gatattcaag atctgcttag gggagatgca gctttgctag atgctccaa
 2341 gaagggtgt ttaccagag tgaagaagt gtctctctc gataatgtaa attgccgca
 2401 taccgaaggc agacattcaa cactttaca tttagcagct ggtataata attagaagt
 2461 tgcagagtat ttgttacaac acggagctga tgtgaatgcc caagacaaag gaggacttat
 2521 tctttacat aatgcagcat ctacgggca ttagatgta gcagctctac taataaagta
 2581 taatgcatgt gtcaatgcca cggacaaatg ggttttaca cctttgcacg aagcagccca
 2641 aaaggagca acacagctt gtgcttgtt gctagcccat ggagctgacc cgactctta
 2701 aaatcaggaa ggacaaacac cttagattt agttcagca gatgatgta gcgctctct
 2761 gacagcagcc atgccccat ctgcttgc cctttgtac aagcctcaag tgcataatgg

2821 tgtgagaagc ccaggagcca ctgcagatgc tctctcttca ggtccatcia gcccatcaag
 2881 ccttcttga gccagcagtc ttgacaactt aictgggagt tticagaac tgtcttcagt
 2941 agttagtca agtggacag aggggtcttc cagtttgag aaaaaggagg ttccaggagt
 3001 agatttagc ataactcaat tctgaaggaa tcttgactt gaggacctaa tggatalatt
 3061 tgagagagaa cagatcactt tggatgtatt agttgagatg gggcacaaagg agctgaagga
 3121 gattggaatc aatgcttatg gacataggca caaactaatt aaaggagtcg agagacttat
 3181 ctccggacaa caaggcttta acccatattt aacttgaac acctctggtg gtggaacaat
 3241 tcttatagat ctgtctctg atgataaaga gtttcagtct gtggagggaag agatgcaaaag
 3301 tacagttcga gaggacagag atggagggtca tgcagggtgga atcttcaaca gatacaatat
 3361 tctcaagatt cagaagggtt gtaacaagaa actatgggaa agatacactc accggagaaa
 3421 agaagtttct gaagaaaacc acaaccatgc caatgaacga atgctatttc atgggtctcc
 3481 tttgtgaat gcaattatcc acaaaggcct tcatgaaagg catgctaca taggttggtat
 3541 gtttgagct ggcaattatt ttgtgaaaa ctcttccaaa agcaatcaat atgtatatgg
 3601 aattggagga ggtactgggt gtccagtcca caaagacaga tctgttaca ttgccacag
 3661 gcagctgctc ttggccggg taaccttggg aaagcttctc ctgcagtcca gtgcaatgaa
 3721 aatggcacat tctctccag gtcacactc agtactggt agggccagtg taaatggcct
 3781 agcattagct gaatatgtta ttacagagg agaacaggct taccctgagt attaatatc
 3841 ttaccagatt atgaggcctg aagggtatgt cgtatgataa atagtattt taagaaacta
 3901 attccactga acctaaaac atcaaacgag cagtggcctc tacgtttac tctttgctg
 3961 aaaaaaatc atctgcccc caggcctgtg gcaaaaggat aaaaatgta acgaagtta
 4021 acattctgac ttgataaagc tttaataatg tacagtgttt tctaaatat tctgtttt
 4081 tcagcacttt aacagatgcc attccaggtt aaactgggtt gtctgtacta aattataaac
 4141 agagttaact tgaacctttt atatgttatg catgatctt acaaacctgt aatgccctca
 4201 acagaactaa tttaactaat acaatactgt gttctttaa acacagcatt tacactgaat
 4261 acaattcat ttgtaaaact gtaataaaga gctttgtac tagccagta ttatttaca
 4321 ttgcttgta atataaatct gtttagaac tgcagcgggt taaaaattt ttcatatgt
 4381 attgttcat tatactcat ctacatcgt catgattgag tgaatttac attgatcc
 4441 agaggctatg ttcagtgtt agttgggaaa gattgagta tcatgataa ttgccgatg
 4501 ggagccttta tctgtatta gaaatcttc tcatlaaga actatgaat atgctgaaga
 4561 ttaattgt gataacctg tatgtatgag acacattcca aagagctcta actatgatag
 4621 gtcctgatta ctaaagaagc tctttactg gcccaatt ctgcttca tgttggaana
 4681 tttctgag tcttctgtg aaaattagag caaagtgcct ctgtttta gagaaactaa
 4741 atctgtctg tgaacaatta ttgtgtctt ttcatggaac ataagtagga tgttaacatt
 4801 tccagggtgg gaagggtaat cctaaatcat ttcccaatct attctaata ccttaaatct
 4861 aaaggggaaa aaaaaaatca caaacaggac tgggtagtt ttatccaa gtatatattt
 4921 tctgttctt ttacttgggt ttattgtctg tattatagc caatctatc atcatgggt
 4981 aacttaacc agaactataa aatgtagtgt ttcatgtccc ctccagcct cctgaatggg
 5041 caagtgcagt gaaacagggt ctctgtctc ctgggtttc tctccatgat gttatgccca
 5101 attggaata tctgtcagt ttgtgcacca tatgtgacc acgccigtgc tcatgttggc
 5161 agctatagaa ggaatgctg tccataaaa tgcctccct attctaata taacactctt
 5221 ttccaggaag catgcttaag catcttgta cagagacata catccattat ggcttgcaa
 5281 tctctttat ttgtgactc tagctccctt caaagtcgag gaaagatctt tactcacit
 5341 atgaggacat tcccatcac tgtctgtacc agtcaccct tatttactt ttattcagt
 5401 ctgtaaaata actggccctt tgcagtaact tglacataa gtgctagaaa atcatgtcc
 5461 ttgtctgag taagagttaa tcatgtaag tgcattctg gattgttct tgtatgtaa
 5521 attatgatca ttatttga agtcaaatcc tcatcttga gtgctttta tacagctctc
 5581 taataattac aaatatccga aagtcattc ttggaacaca agtgagatg gccaaattt
 5641 atatgaattt ttcatattt ctatgctcc aggttttata attagaagat aatgagagaa
 5701 ttaatgggtt ttatattac attatctct aactatgtag ccatattac taccctatg
 5761 agtgaatctg gaattgttt tcatgtgaaa tcatgtgtt ctatgagttt acaatactgc

5821 aaactgtgtt attttaicta aaccattgct taatgagtgt gttttccat gaatgaatat
5881 accgtgggtc atatgttagc atggcagcat tticagatag cttttgttt gtggggaagt
5941 tgggggtttg gggggagggg gagtattagt acgttgcag gaatagccta cttataatg
6001 atgggaatgc ttttctttt gtttgggat tttttttt gaagtgaat ttaactttt
6061 gtgccagtag tactattata cccatcttca gtgtcttact tgtactgtat caaatccat
6121 accctcattt aattcttaat aaaactgttc acttgtaaaa aaaaaaaaaa aaaaaaaaaa
6181 aaaaaaaaaa

Figure 14

1 cgcggcccca gccccggggg cagggaagc ctaattacg gaattaccgc gagcaaggag
 61 cgcgggaatcg gggagcgicc ggagctagct ggaicctta ggcaggatgg tgatgggaat
 121 ctttgcaaat tgaicttict gttgaaagt gaagtactta cctcagcagc agaagaaaaa
 181 gctacaaact gacattaagg aaaatggcgg aaagttttc ttctgttaa atcctcagt
 241 cacacalata atcttagata atgctgatgt tctgagtcag taccaactga attctatcca
 301 aaagaaccac gticatatg caaaccacaga tttatatgg aaatctatca gagaaaagag
 361 actcttgat gtaaagaatt atgacctta taagccctg gacatcacac caccctctga
 421 icagaaggcg agcagttctg aagtgaaac agaaggctta tgcgggaca gtgccacaga
 481 ggagggaagac actgtggaac tcaactgagtt tggatgcag aatgttgaat ttctcatct
 541 tctcaagat ttgaagtig caaaatataa caccctggag aaagtgggaa tggagggagg
 601 ccaggaagct gtgggtggg agcttcagt ttcggggac tccagggact gtctttcct
 661 gatacctca cacttctcc tggatgatgg catggagact agaagacagt ttgtataaa
 721 gaaaacctct gaagatgcaa gtgaatact tgaataaac attgaagaac tgaagaaca
 781 aggatttcta ctaagagaac attcacacc tgaagcaacc caattagcat ctgaacaatt
 841 gcaagcattg ctttggagg aagtcatgaa tcaagcact ctgagccaag aggtgagcga
 901 tttagtagag atgattggg cagaggccct gggccaccig gaacacatgc ttctcaagcc
 961 atgaacagg attagctca acgatgtgag caaggcagag gggattctcc ttctagtaa
 1021 ggcagcactg aaaaatggag aaacagcaga gcaattgcaa aagatgatga cagagttaa
 1081 cagactgata cctcacaag gcacaatgcc caaagaagt aacctgggac tttggctaa
 1141 gaaagcagac ctctgccagc taataagaga catggtaat gtctgtgaaa ctaattgtc
 1201 caaaccaac ccacatccc tggccaata ccgagcttg aggtgcaaaa ttgagcatgt
 1261 tgaacagaat actgaagaat ttctcagggt tagaaaagag gtttgcaga atcaccag
 1321 taagagccca gtggatgct tgcagatatt tagagttggc agagtgaatg aaaccacaga
 1381 gttttgagc aaacttgta atgtgaggcc ctgttgcat ggttctctg tacaaaacat
 1441 cgtgggaatc ttgtgtgag ggttgcctt acccaagta gtggaagac gtgtgtgca
 1501 aagaacagac gtcggaaacc ttggaagtgg gatttattc agtgattcgc tcagtacaag
 1561 tatcaagtac tcacaccgg gagagacaga tggcaccaga ctctgtcica ttgtgacgt
 1621 agccctcggg aagtgtatg acttacatga gaaggactt ccttaactg aagcaccacc
 1681 aggttacgac agtgtcatg gagtttcaca aacagcctct gtcaccacag actttgagga
 1741 tgatgaatt gtgtctata aaaccaatca ggttaaatg aatatatta ttaattttc
 1801 catgcctgga gatcagataa aggacttca tcttagtgat catactgaat tagaggaata
 1861 cagacctgag tttaaaatt tttaaaagg tgaagattac cagtaccag atgcaaaaac
 1921 ttccagcagc accaaggccg gcctccagga tgccttggg aacttggtc ctctggagga
 1981 tgtccacac aaaggagaa tcatagacac ttagcccg gtcattgtt ttacacata
 2041 cacaataaa agtcacgtgc ccattgagc aaaaataic ttccittgg atgacaaggc
 2101 cgtgtgtgt ggttcgaag ccttcatca tgggaagcac atagttggag agattaaaga
 2161 gaaggagaa gccagcaag agtacctaga agccgtgacc cagggccatg gcgcttacct
 2221 gatgagtcag gatgtccgg acgttttac tglagtgtt ggaaacttac ccctaaggc
 2281 taaggttct ataaaaata cctacatcac agaactcagc atctgggca ctgttggtg
 2341 cttttcatg cccgccacc tagcaccctg gcaacaggac aagccttga atgaaaacct
 2401 tcaggataca gtgagaaga ttgtataaa agaaatagga acaagcaaa gcttctctt
 2461 gactatgtct attgagatgc cgtatgtat tgaattcatt ttactgata cacatgaact
 2521 gaaacaaaag cgcacagact gcaagctgt cattagcacc atggaaggca gctccttaga
 2581 cagcagtgga ttttctccc acatcggtt gtctgtgcc tatctccaa gaatgtggg
 2641 tgaanaacat ccagaaaaag aaagcgaggc ttgcatgct gctttcaac ccgatctga
 2701 tgtcgacct cctgacctag ccagtggag cgaagtgtt attgtctg actgtccag

2761 ttccatggag ggtgtgacat tcttgaagc caagcaaatc accttgcag cgctgtcct
 2821 ggtgggtgag aagcagaaag taaatattat ccagttcggc acaggttaca aggagctatt
 2881 ttcgtatcct aagcataca caagcaatac cacggcagca gagttcalca tgtctgccac
 2941 acctaccatg gggaacacag actcttgga aacactccga taicttagct tattgtacc
 3001 tgcctgaggg tcacggaaca tccctctggt gtcctgatggg caccctcagg atgagagcct
 3061 gacattacag ctctgtgaaga ggagccgccc gcacaccagg ttattcgct gcggtatcgg
 3121 ttctacagca aatcgtcacg tcttaaggat ttgtcccag tgtgggtccg gattattga
 3181 atattttaat gcaaaatcca agcatagtig gagaaaacag atagaagacc aaatgaccag
 3241 gctatgttct ccgagttgcc actctgtctc cgtcaaatgg cagcaactca atccagatgc
 3301 gcccagggcc ctgcaggccc cagcccagg gccaaccttg tticgcaatg atcgactcct
 3361 tgtctatgga ttactctc actgcacaca agcaactctg tgtgactaa ttcaagagaa
 3421 agaatttgt acaatggtgt cgactactga gcttcagaag acaactggaa ctatgatcca
 3481 caagctggca gcccgagctc taalcagaga ttatgaagat ggcatcttc acgaaaatga
 3541 aaccagtcac gagatgaaaa acaaacctt gaaatctctg attattaac tcagtaaga
 3601 aaactctctc ataacacaat ttacaagctt tgtggcagtt gagaaaagg atgagaatga
 3661 gtcgcctttt cctgatattc caaaagtgc tgaacttatt gccaaagaag atgtagactt
 3721 cctgccttac atgagctggc aggggggagcc ccaagaagcc gtcaggaacc agtctcttt
 3781 agcatcctct gagtggccag aattacgtt atccaaacga aaacatagga aaattccatt
 3841 ttccaaaaga aaaatggaat tatctcagcc agaagttct gaagatttg aagaggatgg
 3901 cttagggtga ctaccagctt tcacatcaa ttgggaacgt ggagggtgg aaaagctatt
 3961 ggaattaaat tggacagagt catgtaaac aacagcaact gaaccactat ttaagaaatg
 4021 cagttcaatg gaaacatcta ctctagctt ttctctatt ttggctccg ccgttggttc
 4081 ctatctacc ccgactaccc gcgctcacag tctgtctcc ttgtcttg cctcatatc
 4141 tcaggtagct agttcgggt cagctgtcc tccagacag ttgatgcat ctcaattcag
 4201 ccaaggccct gtgcctggca ctgtgtga ctggatccca cagtcggcgt ctgtcccac
 4261 aggacctccc cagaacccac ctctgcacc ctattgtggc attgtttt cagggagctc
 4321 attagctct gcacagctc ctccactgca acatcctgga ggcattacta ccaggcctc
 4381 tgcctggcacc ttccctgagc tggattctcc ccagttcat ttctcttc ctacagacc
 4441 tgatcccatc agaggtttg ggtcttaca tccctctgct tactctct ttattttca
 4501 acctccgca gcctcttga ctgccaacct taggctgcca atggcctctg ctttacctga
 4561 ggctcttgc agtcagctcc ggactacccc agtagatctc tgtctctag aagaatcag
 4621 aggcagctc gaaggaagtc gatgtcctgt cttgtcttt caaagtctg acacagaaag
 4681 tgatgagcta tcagaagtac ttcaagacag ctgctttta caaataaagt gtgatacaaa
 4741 agatgacagt atcccgtgct ttctggaat aaaagaagag gatgaaatag tgtgcacaca
 4801 aactggcag gatgctgtgc ctggacaga actcctcagt ctacagacag aggaaggctt
 4861 ctggaaactt acaccagaac tgggacttat attaatctt aatacaaatg gtttcacag
 4921 ctctttaa caaaaaggca ttcaatctt aggtgtaaaa ggaagagaat gtccttga
 4981 cctaattgcc acaatgctgg tactacagt ttctgcacc aggttggaag aagaggggaat
 5041 agtgttcaaa tcactgatga aaatggatga cctcttatt tccaggaata ttccctggc
 5101 tttagaggca ataaagcaag caagtgaatg ggtaagaaga actgaaggac agtaccatc
 5161 tatctgccc cggcttgaac tggggaacga ctgggactct gccaccaagc agttgctggg
 5221 acaccagccc ataagcactg tgcctctct tcatagagtc ctccattaca gtcaaggcta
 5281 agtcaaatga aactgaatt taaactttt gcatgctct atgtagaaa taatcaaatg
 5341 ataatagata attataatga aacttatta aggtttcatt cagttagca attactgtc
 5401 ttaaaaatta agtggagaa gaattactt aatcaactaa caagcaataa taaaatgaaa
 5461 cttaaaataa aaaaaaaaa aaaaaaaaa